BridgeBio Pharma BBIO
NASDAQ BBIO
$67.25 +0.34 (+0.51%)
At close: Oct 2, 2026 · 4:00 PM EDT

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)

Updated

BridgeBio Pharma (BBIO) recorded Asset Writedowns and Impairment of $271,000 in FY2024.

Analysis

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022) Analysis & Trends

  • Per Business Quant data, BBIO's Asset Writedowns and Impairment was $12.72 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 BridgeBio Pharma 13.13 Bn 10.25 Bn 228.63 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 67,000.00
Mar 31, 2022 12.65 Mn
Dec 31, 2021 -3.30 Mn
Mar 31, 2021 3.30 Mn
API Access

BridgeBio Pharma Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=BBIO&period=max&api_key=YOUR_API_KEY